{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T05:27:16Z","timestamp":1741066036030,"version":"3.38.0"},"reference-count":29,"publisher":"SAGE Publications","issue":"1_suppl","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2003,10]]},"abstract":"<jats:p> Stavudine is a potent nucleoside analogue and a well-recognized component of highly active antiretroviral therapy. Clinical trials have shown stavudine to have a superior or at least comparable virological efficacy and immune reconstitution when compared with other nucleoside analogues. Studies have shown that the prevalence of phenotypic resistance to stavudine is low compared with that of zidovudine, lamivudine and abacavir, and any loss of sensitivity to stavudine is slow to develop and of low intensity. Stavudine has a low incidence of clinically significant adverse events, and those experienced are generally long-term, manageable class effects. <\/jats:p>","DOI":"10.1258\/095646203322491842","type":"journal-article","created":{"date-parts":[[2003,10,21]],"date-time":"2003-10-21T19:53:17Z","timestamp":1066765997000},"page":"20-28","source":"Crossref","is-referenced-by-count":1,"title":["The reassurance of experience"],"prefix":"10.1177","volume":"14","author":[{"given":"E","family":"Martf\u00ednez","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Hospital Clinic-IDIBAPS, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2003,10,1]]},"reference":[{"key":"bibr1-095646203322491842","unstructured":"Schnittmari S, Reynolds L, Ledeine J. Study 094: Assessment of intrinsic antiviral activity of nucleoside analogues (NA) during short-course monotherapy [Poster H-160]. 32nd Inter science Conference on Antimicrobial Agents and Chemotherapy, San Diego"},{"key":"bibr2-095646203322491842","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-5-199703010-00003"},{"key":"bibr3-095646203322491842","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200007280-00015"},{"key":"bibr4-095646203322491842","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200006160-00014"},{"key":"bibr5-095646203322491842","doi-asserted-by":"publisher","DOI":"10.1086\/314891"},{"key":"bibr6-095646203322491842","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200007280-00016"},{"key":"bibr7-095646203322491842","unstructured":"Gilead Sciences Inc. Gilead Announces Preliminary 48-week Study Results Showing Viread\u2122 Comparable to Stavudine in Treatment-na\u00efve HIV Patients. Gilead Press Release, 7 May 2002. Cambridge Gilead Sciences, 2002"},{"key":"bibr8-095646203322491842","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199904160-00009"},{"key":"bibr9-095646203322491842","unstructured":"Foudraine N, Weverling G, Jurrianns S,  Remarkably sustained virologie response after indinavir addition to suboptimal AZT\/3TC and d4T\/3TC therapy: 72 weeks follow-up [Abstract 635]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago 1999"},{"key":"bibr10-095646203322491842","unstructured":"Rubio R, Pulido F, Martin J,  Combination therapy with AZT+3TC+indinavir vs. d4T+3TC+indinavir in pretreated patients with less than 200 CD4\/mm3 [Abstract 379]. 5th Conference on Retroviruses and Opportunistic Infections, Chicago 1998"},{"key":"bibr11-095646203322491842","unstructured":"Baril JG, Pollard RB, Raffi F,  Stavudine extended\/prolonged (XR\/PRC) vs stavudine immediate release (IR) in combination with lamivudine and efavirenz: 48 week efficacy and safety [Poster LbPeB9014]. XIV International AIDS Conference, Barcelona 2002"},{"key":"bibr12-095646203322491842","unstructured":"Larder B, Wang D, Harrigan R. Identification of a set of \u2018nucleoside associated mutations\u2019 (NAMs) that are the common cause of nucleoside cross-resistance [Abstract 06]. 3rd European Symposium on the Clinical Implications of HIV Drug Resistance, Frankfurt 2001"},{"issue":"1","key":"bibr13-095646203322491842","first-page":"38","volume":"6","author":"Larder BA","year":"2001","journal-title":"Antivir Ther"},{"key":"bibr14-095646203322491842","unstructured":"Moyle GL, Law M, Sawyer AW,  A meta-analysis of changes in haemoglobin, CD4 and viral load over 24 and 48 weeks across six randomised trials of highly active antiretroviral therapy regimens comparing stavudine and zidovudine in treatment-na\u00efve individuals [Poster 94]. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego 2002"},{"journal-title":"XIV IAC","year":"2002","author":"Staszewski S","key":"bibr15-095646203322491842"},{"key":"bibr16-095646203322491842","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200107270-00008"},{"key":"bibr17-095646203322491842","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200301010-00007"},{"key":"bibr18-095646203322491842","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.2.222"},{"key":"bibr19-095646203322491842","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04056-3"},{"key":"bibr20-095646203322491842","unstructured":"Dube MP, Zackin R, Tebas P,  Prospective study of regional body composition in antiretroviral-na\u00efve subjects randomized to receive zidovudine+lamivudine or didanosine+stavudine combined with nelfinavir, efavirenz, or both: A5005s, a substudy of ACTG 384 [Abstract 27]. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Infection, San Diego 2002"},{"key":"bibr21-095646203322491842","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.2.207"},{"key":"bibr22-095646203322491842","unstructured":"Tashima K, Morales-Ramirez J, Butcher D,  Impact on fat loss of ZDV+3TC backbone: abdominal CT-scan sub-study of Study DMP 266-006 [Abstract 737]. 10th Conference on Retroviruses and Opportunistic Infections, Boston 2003"},{"key":"bibr23-095646203322491842","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.10.3191.010k10_3191_3198"},{"key":"bibr24-095646203322491842","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200210180-00005"},{"key":"bibr25-095646203322491842","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.716-723.2002"},{"key":"bibr26-095646203322491842","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200102160-00015"},{"key":"bibr27-095646203322491842","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012035"},{"key":"bibr28-095646203322491842","unstructured":"Lopez S, Miro O, Garcia M,  Assessment of mitochondrial toxicity of diverse HAART regimens by a simultaneous genetic and biochemical approach [Abstract PL 14.1]. 6th International Congress on Drug Therapy in HIV Infection, Glasgow 2002"},{"key":"bibr29-095646203322491842","doi-asserted-by":"publisher","DOI":"10.1086\/339041"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1258\/095646203322491842","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1258\/095646203322491842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T08:12:17Z","timestamp":1740989537000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1258\/095646203322491842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":29,"journal-issue":{"issue":"1_suppl","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["10.1258\/095646203322491842"],"URL":"https:\/\/doi.org\/10.1258\/095646203322491842","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"type":"print","value":"0956-4624"},{"type":"electronic","value":"1758-1052"}],"subject":[],"published":{"date-parts":[[2003,10]]}}}